Endostatin: Are the 2 years up yet?

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3758-3760

  Schellens, Jan H M ^a   Ratain, Mark J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN DERIVATIVE; PROTEOGLYCAN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG ACTIVITY; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; STOMACH CANCER; TUMOR BIOPSY; VASCULARIZATION; XENOGRAFT;

EID: 0037106499     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.18.3758     Document Type: Editorial

References (22)

1. Two drugs eradicate tumors in mice
2. Study of the media's influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial
3. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs
4. What is the evidence that tumors are angiogenesis dependent?
5. Angiogenetic therapy of experimental cancer does not induce acquired drug resistance
6. Patterns of emerging mechanisms of angiogenetic switch during tumorigenesis
7. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
8. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
9. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer
10. Collagen XVIII is a basement membrane heparin sulfate proteoglycan
11. Cloning, expression and in vitro activity of human endostatin
12. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution
13. Angiostatin and endostatin: Endogenous inhibitors of tumor growth
14. Development of target-based antineo-plastic agents
15. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
16. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model
17. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
18. Phase I study of recombinant human endostatin in patients with advanced solid tumors
19. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin
20. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
21. Gene expression profiling predicts clinical outcome of breast cancer